Pulse Explorar nav.journalClub Debates Tendencias Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma | Synapse

June 25, 2003Open Access

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Bortezomib, a member of a new class of anticancer drugs, is active in patients with relapsed multiple myeloma that is refractory to conventional chemotherapy.

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Richardson et al. (Wed,) studied this question.

synapsesocial.com/papers/69c9f1a1937a4bbd1a83b1de https://doi.org/https://doi.org/10.1056/nejmoa030288

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1In vivo ubiquitination and proteasome-mediated degradation of p53(1).1996 · 649 citations
2Role of the Ubiquitin-Proteasome Pathway in Regulating Abundance of the Cyclin-Dependent Kinase Inhibitor p271995 · 1,835 citations
3Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation.1996 · 493 citations
4Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B1996 · 568 citations
5Proteasome inhibitors: a novel class of potent and effective antitumor agents.1999 · 1,481 citations